AR and posterior cortical atrophy: The in vitro study performed by Qu et al. [79] aimed to study the antitumor effects of proxalutamide and two others currently used androgen receptor (AR) antagonists (bicalutamide and enzalutamide) on AR-positive (LNCaP and 22RV1) and AR-negative PCa cell lines through liquid chromatography quadrupole time-of-flight mass spectrometry (LC-Q/TOF-MS).